Immunome (IMNM) Guggenheim Securities 2nd Annual Healthcare Innovation Conference summary

Strategic focus and company vision

• Emphasis on building a pure-play cancer company focused on targeted therapies, including antibody-based, radioligand, and small molecule approaches.

• Decision to avoid broader modalities like cell and gene therapy to maintain focus and leverage existing expertise.

Varegacestat clinical development and market opportunity

• Varegacestat, a gamma-secretase inhibitor for desmoid tumors, has completed phase 3 enrollment with pivotal data expected this quarter.

• Phase 2 data indicated superior efficacy and once-daily dosing compared to the approved competitor, Ogsiveo (nirogacestat).

• Market opportunity is substantial, with high annual therapy costs and a rare but impactful disease population.

• The company is prepared for product launch, with manufacturing and regulatory teams in place.

Clinical trial design and differentiation

• Patient populations in the pivotal trial are nearly identical to those in the competitor's study, ensuring comparability.

• The trial uses FDA gold-standard radiologic assessment for endpoints, aiming for clear differentiation in objective response rate and tumor reduction.

• Key efficacy benchmarks are set at exceeding 41% ORR and 59% median tumor reduction, with additional endpoints including pain and progression-free survival.